{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218282","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2026-05-12T12:48:29+00:00","discovered_at":"2026-05-12T12:50:00.311602+00:00","generated_at":"2026-05-12T12:52:04.815567+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Coya Therapeutics enters $30M at-the-market equity offering with Leerink Partners","bullets":["Sales Agreement with Leerink Partners allows up to $30M gross proceeds from common stock sales on Nasdaq.","Leerink receives 3.0% commission on gross proceeds; Company may sell at its discretion.","Offering under existing shelf registration; no minimum obligation to sell."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218282","json":"https://secwatch.observer/filing/0001193125-26-218282.json","markdown":"https://secwatch.observer/filing/0001193125-26-218282.md","text":"https://secwatch.observer/filing/0001193125-26-218282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526218282/0001193125-26-218282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526218282/d938051d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:52:04.815567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cc1f01d47567f1d26d85102cb97e347821f1f740","claim":"Coya Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $30,000,000 (effective 2026-05-12).","evidence_excerpt":"On May 12, 2026, Coya Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC, as sales agent (“Leerink Partners”), pursuant to which the Company may offer and sell, from time to time through or to Leerink Partners, shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), for aggregate gross proceeds of up to $30,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000119312526218282/0001193125-26-218282-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Leerink Partners LLC"},{"label":"Value","value":"up to $30,000,000"},{"label":"Effective","value":"2026-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}